Our view on Resmed (RMD) is different to the other brokers

Michael Gable
Fairmont Equities
Our view on Resmed (RMD) is different to the other brokers. Of the 8 covering it, 7 rate it as a buy, with one neutral. When everyone is bullish, the contrarian trade normally wins out, doesn't it? You can read our views on RMD via the following link: (VIEW LINK) For a copy of the full report containing other trading and investment ideas, visit our website (VIEW LINK)

Michael Gable
Managing Director
Fairmont Equities
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...
Expertise
No areas of expertise
most popular
Equities
6 stocks for a full portfolio reset in 2023
Livewire Markets
Equities
The WA copper miner poised for a global breakout
Livewire Markets
Please sign in to comment on this wire.